Enter Note Done
Go to previous page in this tab
Event
  • Scientific Session
  • Bookmark Icon
  • Quantitative In Vitro to In Vivo Extrapolation for Consideration in Chemical Safety Decisions: Bridging Platforms, Endpoints, and Regulatory Needs
  • Schedule
    Notes
  • Room 304‚ Convention Center
    Set Timezone


Chair: Yitong Liu, US FDA
Co-Chair: Matthew Linakis, Ramboll Americas Engineering Solutions Inc.

Primary Endorser: In Vitro and Alternative Methods Specialty Section


Endorser(s): Biological Modeling Specialty Section


Endorser(s): Risk Assessment Specialty Section


Regulatory agencies worldwide face increasing demand to evaluate chemical safety using human-relevant in vitro data rather than traditional animal studies. Quantitative in vitro–to–in vivo extrapolation, or QIVIVE, has emerged as a critical bridge, using physiologically based kinetic models (PBK) and reverse dosimetry to translate in vitro bioactivity concentrations into human equivalent administered doses. While rapid advances in high-throughput screening, open-source modeling tools, and international guidance have accelerated the science, important questions remain: How reliably can QIVIVE-derived values inform safety decisions? What are the trade-offs between model complexity and throughput? And what level of confidence is sufficient for regulatory application? The central objective of this session is to examine the current state and potential of QIVIVE to inform chemical safety considerations across diverse chemical classes, toxicological endpoints, and regulatory frameworks. By spanning hepatotoxicity, developmental toxicity, and developmental neurotoxicity — and ranging from high-throughput screening of data-poor chemicals to single-compound translational case studies to international regulatory guidance — the session explores the generalizability and evolving applicability of current QIVIVE approaches. A common thread across all three presentations is the use of PBK model-based reverse dosimetry to derive human equivalent doses from in vitro bioactivity data, and the comparison of these QIVIVE-derived values against available in vivo benchmarks to assess predictive performance. To address this objective, the session brings together three speakers spanning US and European regulatory agencies and industry to address these questions through complementary perspectives. The first presentation surveys the rapidly expanding landscape of QIVIVE workflows and then demonstrates a high-throughput approach that pairs in vitro screening data with generic and bespoke pharmacokinetic models to estimate human oral equivalent doses for prioritization and risk assessment of data-poor chemicals. The second presentation provides a translational case study from the US Food and Drug Administration, demonstrating how mechanistic in vitro findings from multiple hepatic cell models, combined with Bayesian dose-response analysis and three independent modeling platforms, can predict potential human-relevant toxic doses for a botanical constituent with known clinical hepatotoxicity. The third presentation offers the European regulatory perspective, describing how the Organisation for Economic Co-operation and Development (OECD) and the European Food Safety Authority (EFSA) are operationalizing QIVIVE principles through physiologically based kinetic modeling to support the use of in vitro developmental neurotoxicity battery data in human health risk assessment of pesticide active substances, including proposed minimum data requirements, considerations for in vitro distribution kinetics, a reporting framework for regulatory submissions, and key sources of uncertainty.The session concludes with a moderated panel discussion on cross-cutting challenges, including uncertainty quantification, international harmonization of modeling approaches, the role of in vitro kinetics in improving extrapolation accuracy, and the practical steps needed to move QIVIVE from case studies to routine regulatory application. Attendees will gain a comprehensive understanding of both the current capabilities and the remaining gaps in the translation of in vitro toxicity data into potential in vivo safety decisions.
Session and Activity Type
Presentations